TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06157047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crestal Bone Expansion obtained with the Magnetic Mallet®
Description: A magnetodynamic instrument (Magnetic Mallet®, Metaergonomica, Turbigo, Italy) has been used to perform a horizontal bone expansion in edentulous sites that need to be rehabilitated with a dental implant.
Study: NCT01595659

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passenger
Description: Driving with risk accepting or risk averse passenger

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passenger
Description: Driving with risk accepting or risk averse passenger

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Passenger
Description: Driving with risk accepting or risk averse passenger
Study: NCT02813759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
Study: NCT02357797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vortioxetine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02795546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate sodium
Description: 400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: beta-tricalcium phosphate bone substitute
Description: beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-tricalcium phosphate bone substitute
Description: beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
Study: NCT02051725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active life-style intervention
Study: NCT00399594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A
Description: LV lead placement in region of latest mechanical velocity (tissue doppler)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: B
Description: LV lead placement in standard (lateral / posterolateral) position.
Study: NCT00137995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytosine Arabinoside
Description: 2000 mg/m²/12 h D2 D3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg From D1 to D4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300mg/m² on D-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCNU
Description: 300mg/m² on D-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m² from D-6 to D-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m² from D-6 to D-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m² from D-6 to D-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 100 mg/m² from D-6 to D-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m² on D-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m² on D-2
Study: NCT03125863

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AquaBeam System
Description: The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
Study: NCT02853565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN008
Description: The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
Study: NCT00962702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LAAx TigerPaw System
Description: Exclusion of Left Atrial Appendage
Study: NCT04055246

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 9 grams of food grade inulin added to custom made fiber bars.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (maltodextrin)
Description: 9 grams of food grade maltodextrin - replaces inulin in fiber bars.
Study: NCT03777696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 μg of buccal misoprostol
Study: NCT02265172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard practice
Description: Orthopaedic surgeon assessment
Study: NCT00986570

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin A
Description: 100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
Study: NCT02795637

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasotraline
Description: dasotraline 8mg capsule/day
Study: NCT00621036

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous immunoglobulin idiotype-KLH conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT02164630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hope Therapy
Description: Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.

Intervention type: OTHER
Group type: OTHER
Intervention: Pain Education
Description: Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
Study: NCT01648504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eGuide to Colonoscopy and in office ipad education
Description: The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
Study: NCT02546349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol, tiotropium
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol, tiotropium
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone/salmeterol, tiotropium
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone/salmeterol, tiotropium
Description: In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
Study: NCT03165877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-glycemic index
Description: Subjects ate low-glycemic index lunches and dinners (\<55%),consisting of salad, main course and dessert, respectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects ate standard lunches and dinners (\>60%),consisting of salad, main course and dessert, respectively.
Study: NCT00563680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand-dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
Study: NCT01801683

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention-using PEARLS
Description: The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
Study: NCT03352895

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: Grape seed extract 100mg Microcrystalline Cellulose 90mg Magnesium Stearate 2mg Gelatin 100mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The gel contains a mixture of glucose and maltodextrin - a complex carbohydrate - along with fat and a trace of protein.
Study: NCT01060475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705 and tacrolimus
Description: Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705 and tacrolimus
Description: Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo LIM-0705 and tacrolimus
Description: Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug LIM-0705 and placebo tacrolimus
Description: Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
Study: NCT03032861

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice
Description: Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
Study: NCT02408328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate
Description: Loading dose and continues use of caffeine until 44 weeks postmenstrual age

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home monitor
Description: Use of home monitor until 44 weeks postmenstrual age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continued inpatient monitoring until apnea resolution
Description: Continued inpatient monitoring until apnea resolution
Study: NCT00377936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine alone
Description: Gemcitabine monotherapy 1000 mg/m2 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 and Gemcitabine
Description: EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Study: NCT03777696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 μg of buccal misoprostol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: 1 gm of tranexamic acid in 100 ml saline iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TA
Description: 1 gm of tranexamic acid in 100 ml saline iv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to misoprostol
Description: placebo tablets to misoprostol buccal
Study: NCT00377936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 and Gemcitabine
Description: EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EndoTAG-1 and Gemcitabine
Description: EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
Study: NCT03777696

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to TA
Description: 110 ml saline iv
Study: NCT01200940

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 360 mL of water will be drunk 10 minutes prior to a 75 g oral glucose tolerance test
Study: NCT02635581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta TT acetabular cup
Study: NCT04765527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Turmeric Strength for Joint
Description: Turmeric-based tablets

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT01893645

Intervention type: DEVICE
Intervention: Pronto-7
Description: A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
Study: NCT03776292

Intervention type: OTHER
Intervention: monitoring
Description: Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.

Intervention type: OTHER
Intervention: monitoring
Description: Primary outcome; composite 1ry outcome \[1-Dynamic pulmonary compliance monitoring.2- Cardiac Index monitoring\] during and after surgical retractor application compared to the same variables reading prior retractor application and in between both groups. Secondary outcome: Static lung compliance, Cardiac output, Stroke volume SV - stroke volume variability (SVV)-Cardiac performance index, O2 delivery DIO2. Noninvasive Intraoperative hemodynamic (MBP, HR, O2 saturation)\] during and after surgical ring retractor application compared to the same variable reading prior retractor application and in between both groups.
Study: NCT00826579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node procedure
Description: After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration
Description: Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
Study: NCT01817192

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant Chemotherapy
Description: Patients who have undergone complete resection of NSCLC that has been documented histologically to be non-squamous and that is pathological Stage I or IIA, will undergo testing with the 14-Gene Prognostic Assay. Patients determined to be intermediate or high risk and who meet all eligibility criteria will be randomized either to observation or to four cycles of adjuvant therapy with a standard NSCLC platinum-based doublet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Radiographic surveillance
Description: Serial radiographic surveillance is a current standard of care for Stage I or Stage IIA lung cancer. All intermediate or high risk patients randomized to observation or chemotherapy will have routine CT Scans at 6 month intervals until 5 years after enrollment and at yearly intervals thereafter until the end of the study period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14-Gene Prognostic Assay
Description: This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 14-Gene Prognostic Assay
Description: This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of Stage I or Stage IIA non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as intermediate or high-risk will be randomized to either adjuvant chemotherapy or observation.
Study: NCT04803188

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance
Description: Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance
Description: Screening MRI examinations will be performed on an MRI General Electric (GE) 3 Tesla MRI using a 32-channel phased array pelvic coil. The imaging protocol will include: T2-weighted morphological and diffusion-weighted functional sequences.~All images will be reviewed by two radiologists experienced in urogenital imaging, who will be blinded to the patients' medical history. Both radiologists in charge will then assign a PI-RADS score (1 to 5) to each lesion for bi-parametric MRI, representing the likelihood of a clinically significant prostate lesion. For the generation of the overall PI-RADS score assigned to each lesion, the PI-RADS score algorithm for non-contrast MRI described in the PI-RADS version 2.1 recommendations will be applied. Lesions scored as bPI-RADS superior or equal than 3 will be directed to MRI-TRUS guided targeted biopsy.
Study: NCT03612739

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 CAR-T Cells
Description: The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 CAR-T Cells
Description: The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2 CAR-T Cells
Description: The treatment consists in six consecutive cycles of AZA, administered at days~1 to 7 of a 28-day cycle. Patients will be treated with 8 injections of NKR-2 at day 9 and 23 of AZA cycles 2-3-4 and 5.
Study: NCT00355472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-0761
Description: IV administration at 4 escalating dose levels.
Study: NCT03848247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of Isotonic saline
Description: Half the participants will be injected in a neck muscle with isotonic saline (Control group) and the other half will get NGF (Neck pain group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection of NGF
Description: Half the participants will be injected in a neck muscle with NGF (Neck pain group).